Aligos Therapeutics downgraded by JP Morgan with a new price target
$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JP Morgan downgraded Aligos Therapeutics from Overweight to Neutral and set a new price target of $12.00 from $30.00 previously